Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203924 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1NPSR1TAAR1 | |
| SCHEMBL19437142 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1NPSR1TAAR1 | |
| SCHEMBL4379957 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1NPSR1TAAR1 | |
| SCHEMBL4386420 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1NPSR1TAAR1 | |
| SCHEMBL3204209 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1NPSR1TAAR1 | |
| SCHEMBL3219056 | 1.00 | ALDH1A1 (0.53) | ALDH1A1GAACPB1NPSR1TAAR1 | |
| SCHEMBL30221997 | 0.90 | ALDH1A1 (0.56) | ALDH1A1GAACPB1TSHRSMN1; SMN2 | |
| SCHEMBL13643316 | 0.90 | CPB1 (0.50) | ALDH1A1GAACPB1TSHRCA1 | |
| SCHEMBL29553101 | 0.90 | TSHR (0.55) | ALDH1A1GAACPB1TSHRCA1 | |
| SCHEMBL9937871 | 0.90 | ALDH1A1 (0.56) | ALDH1A1GAACPB1TSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8815847-B2 | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8765741-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8546602-B2 | 5,6-D hydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120302744-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8236948-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | ALDH1A1 417/4885GAA 1618/4885CPB1 1589/4885 |
| US-20120302744-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | ALDH1A1 205/4885GAA 2633/4885CPB1 3198/4885 |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | ALDH1A1 205/4885GAA 2633/4885CPB1 3198/4885 |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, CCR3, C5 | ALDH1A1 786/4885GAA 2642/4885CPB1 737/4885 |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | THOP1, XDH, DUOX1 | ALDH1A1 16/4885GAA 1717/4885CPB1 2140/4885 |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | ALDH1A1 417/4885GAA 1618/4885CPB1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.